Ampio Pharmaceuticals, Inc.
, a development stage biopharmaceutical company focused on the development of immunology based therapies, was featured on a FOX
segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug,"
reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 (COVID-19) infection is Acute Respiratory Distress Syndrome (ARDS), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.
Michael Macaluso, Ampio CEO, said, "The Company is exploring options that may enable the completion of the AP-013 study, our Phase 3 clinical trial for the treatment of severe osteoarthritis of the knee, during this COVID-19 pandemic. Simultaneously, we have directed our R&D efforts to explore the possible application of the immunomodulatory and anti-inflammatory properties of Ampion in the most severe and lethal complication of the COVID-19 infected patients: ARDS. The FDA has been very responsive, and the Company is grateful for the Agency's efforts as we work together to study the potential benefits of Ampion in this population."